Insider Transactions in Q2 2025 at Akero Therapeutics, Inc. (AKRO)
Insider Transaction List (Q2 2025)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 30
2025
|
Andrew Cheng President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
890
+0.16%
|
$20,470
$23.87 P/Share
|
|
Jun 30
2025
|
Scott A. Gangloff Chief Technology Officer |
BUY
Grant, award, or other acquisition
|
Direct |
299
+1.24%
|
$6,877
$23.87 P/Share
|
|
Jun 30
2025
|
Timothy Rolph Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
890
+0.53%
|
$20,470
$23.87 P/Share
|
|
Jun 30
2025
|
William Richard White Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
890
+1.5%
|
$20,470
$23.87 P/Share
|
|
Jun 30
2025
|
Patrick Lamy Senior VP, Commercial Strategy |
BUY
Grant, award, or other acquisition
|
Direct |
193
+0.6%
|
$4,439
$23.87 P/Share
|
|
Jun 30
2025
|
Jonathan Young Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
890
+0.45%
|
$20,470
$23.87 P/Share
|
|
Jun 30
2025
|
Catriona Yale Chief Development Officer |
BUY
Grant, award, or other acquisition
|
Direct |
890
+0.96%
|
$20,470
$23.87 P/Share
|
|
Jun 20
2025
|
Patrick Lamy Senior VP, Commercial Strategy |
SELL
Open market or private sale
|
Direct |
875
-2.69%
|
$47,250
$54.59 P/Share
|
|
Jun 18
2025
|
Jonathan Young Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
1,453
-0.73%
|
$78,462
$54.84 P/Share
|
|
Jun 18
2025
|
Catriona Yale Chief Development Officer |
SELL
Open market or private sale
|
Direct |
1,633
-1.77%
|
$88,182
$54.84 P/Share
|
|
Jun 18
2025
|
William Richard White Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
1,634
-2.76%
|
$88,236
$54.84 P/Share
|
|
Jun 18
2025
|
Timothy Rolph Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
1,129
-0.67%
|
$60,966
$54.84 P/Share
|
|
Jun 18
2025
|
Scott A. Gangloff Chief Technology Officer |
SELL
Open market or private sale
|
Direct |
848
-3.49%
|
$45,792
$54.84 P/Share
|
|
Jun 18
2025
|
Andrew Cheng President and CEO |
SELL
Open market or private sale
|
Direct |
6,620
-1.19%
|
$357,480
$54.84 P/Share
|
|
Jun 16
2025
|
Patrick Lamy Senior VP, Commercial Strategy |
SELL
Open market or private sale
|
Direct |
2,000
-2.93%
|
$108,000
$54.46 P/Share
|
|
Jun 16
2025
|
Patrick Lamy Senior VP, Commercial Strategy |
BUY
Exercise of conversion of derivative security
|
Direct |
2,000
+5.47%
|
$38,000
$19.87 P/Share
|
|
Jun 16
2025
|
Catriona Yale Chief Development Officer |
SELL
Open market or private sale
|
Direct |
10,000
-3.35%
|
$540,000
$54.7 P/Share
|
|
Jun 16
2025
|
Catriona Yale Chief Development Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+8.91%
|
$210,000
$21.1 P/Share
|
|
Jun 10
2025
|
Jonathan Young Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
2,493
-1.24%
|
$132,129
$53.99 P/Share
|
|
Jun 10
2025
|
Patrick Lamy Senior VP, Commercial Strategy |
SELL
Open market or private sale
|
Direct |
919
-2.74%
|
$49,626
$54.0 P/Share
|
|
Jun 10
2025
|
Catriona Yale Chief Development Officer |
SELL
Open market or private sale
|
Direct |
2,803
-2.95%
|
$151,362
$54.0 P/Share
|
|
Jun 10
2025
|
William Richard White Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
2,804
-4.53%
|
$148,612
$53.99 P/Share
|
|
Jun 10
2025
|
Timothy Rolph Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
2,358
-1.39%
|
$127,332
$54.0 P/Share
|
|
Jun 10
2025
|
Andrew Cheng President and CEO |
SELL
Open market or private sale
|
Direct |
37,837
-2.17%
|
$2,043,198
$54.03 P/Share
|
|
Jun 06
2025
|
Timothy Rolph Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
25,000
-12.84%
|
$1,375,000
$55.04 P/Share
|
|
Jun 06
2025
|
Timothy Rolph Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
25,000
+5.72%
|
$525,000
$21.1 P/Share
|
|
Jun 05
2025
|
Timothy Rolph Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
12,500
-3.48%
|
$662,500
$53.61 P/Share
|
|
Jun 05
2025
|
Timothy Rolph Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
12,500
+6.42%
|
$262,500
$21.1 P/Share
|
|
Jun 03
2025
|
G. Walmsley Graham |
BUY
Grant, award, or other acquisition
|
Direct |
9,398
+44.83%
|
-
|
|
Jun 03
2025
|
Chou Judy |
BUY
Grant, award, or other acquisition
|
Direct |
9,398
+50.0%
|
-
|
|
Jun 03
2025
|
Tomas J. Heyman |
BUY
Grant, award, or other acquisition
|
Direct |
9,398
+50.0%
|
-
|
|
Jun 03
2025
|
Yuan Xu |
BUY
Grant, award, or other acquisition
|
Direct |
9,398
+50.0%
|
-
|
|
Jun 03
2025
|
Mark T Iwicki |
BUY
Grant, award, or other acquisition
|
Direct |
9,398
+50.0%
|
-
|
|
Jun 03
2025
|
Seth Loring Harrison |
BUY
Grant, award, or other acquisition
|
Direct |
9,398
+6.06%
|
-
|
|
Jun 03
2025
|
Jane Henderson |
BUY
Grant, award, or other acquisition
|
Direct |
9,398
+50.0%
|
-
|
|
Jun 02
2025
|
Patrick Lamy Senior VP, Commercial Strategy |
SELL
Open market or private sale
|
Direct |
4,000
-3.61%
|
$200,000
$50.3 P/Share
|
|
Jun 02
2025
|
Patrick Lamy Senior VP, Commercial Strategy |
BUY
Exercise of conversion of derivative security
|
Direct |
4,000
+9.64%
|
$76,000
$19.87 P/Share
|
|
May 22
2025
|
Patrick Lamy Senior VP, Commercial Strategy |
SELL
Open market or private sale
|
Direct |
4,000
-10.67%
|
$200,000
$50.0 P/Share
|
|
May 22
2025
|
Patrick Lamy Senior VP, Commercial Strategy |
BUY
Exercise of conversion of derivative security
|
Direct |
4,000
+9.64%
|
$176,000
$44.37 P/Share
|
|
May 15
2025
|
Catriona Yale Chief Development Officer |
SELL
Open market or private sale
|
Direct |
10,000
-3.28%
|
$390,000
$39.19 P/Share
|
|
May 15
2025
|
Catriona Yale Chief Development Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+8.69%
|
$210,000
$21.1 P/Share
|
|
May 12
2025
|
Andrew Cheng President and CEO |
SELL
Open market or private sale
|
Direct |
30,000
-2.42%
|
$1,230,000
$41.32 P/Share
|
|
May 07
2025
|
Patrick Lamy Senior VP, Commercial Strategy |
SELL
Open market or private sale
|
Direct |
8,000
-10.15%
|
$336,000
$42.54 P/Share
|
|
May 07
2025
|
Patrick Lamy Senior VP, Commercial Strategy |
BUY
Exercise of conversion of derivative security
|
Direct |
8,000
+16.16%
|
$152,000
$19.87 P/Share
|
|
May 06
2025
|
Timothy Rolph Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
12,500
-2.32%
|
$537,500
$43.54 P/Share
|
|
May 06
2025
|
Timothy Rolph Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
12,500
+6.42%
|
$262,500
$21.1 P/Share
|
|
Apr 24
2025
|
Timothy Rolph Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
6,250
-3.55%
|
$256,250
$41.03 P/Share
|
|
Apr 24
2025
|
Timothy Rolph Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
6,250
+3.43%
|
$131,250
$21.1 P/Share
|
|
Apr 15
2025
|
Catriona Yale Chief Development Officer |
SELL
Open market or private sale
|
Direct |
9,073
-4.4%
|
$344,774
$38.21 P/Share
|
|
Apr 15
2025
|
Catriona Yale Chief Development Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
9,073
+8.02%
|
$190,533
$21.1 P/Share
|